Upcoming events

Switch to Calendar View

• 2025 Abstract Submissions

  • Start
    August 15, 2024
  • End
    October 21, 2024
  •  
    11:59 PM
  • Location
    Hyatt Regency Bethesda, Bethesda MD

  Register

  Submitting an Abstract to ASENT

  DEADLINE: October 21, 2024 11:59PM ET

  The Abstract Review Committee is committed to presenting the best in neurotherapeutic research at the ASENT Annual Meeting.

  Abstracts selected for presentation by our esteemed review committee will be presented as either a poster or a pipeline presentation at the ASENT 2024 Annual Meeting which will take place at the Hyatt Regency Bethesda in Bethesda, MD, March 12-14, 2024. 

  All abstracts selected for presentation will be listed in the program and will be published in the society's high impact journal Neurotherapeutics, which is published by Elsevier and led by Editor in Chief, M. Maral Mouradian, MD. 

  The abstract should describe original research broadly relevant to the goal of ASENT, which is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system. Please check your abstract carefully for typographical errors, misspellings, etc. Be sure to include data results.

  All abstracts are evaluated by experts in Neurotherapeutics according to the following criteria and overall merit: 

  1. Scientific or clinical impact
  2. Quality of data, analysis, and presentation
  3. Relevance to the discovery and/or development of neurotherapeutics and inclusion of novel targets or new initiatives.
  4. Abstracts must be submitted, presented, and cited in English.

  Upon registering and paying the abstract fee, you will be sent a confirmation email with a link to the Abstract Submission System. If you have not used our partner, Oxford Abstracts, you will be asked to create an account. This will allow you to edit your submission as needed.

  Below you will find details regarding Posters, Pipeline, Guidelines, Eligibility and the benefits of submitting.

  GUIDELINES

  Title: Sentence Case (Max 50 Words)
  Abstract Body: One Paragraph with no subheadings and no tables or graphs (Max 250 Words) Include a sentence on study's purpose, brief description of methods, summary of results, and statement of conclusions reached.
  Authors: Sentence Case

  ELIGIBILITY FAQs 

  - Encore Abstracts, those that have been previously presented at other recent scientific meetings, or submitted for consideration to other scientific meetings, are welcome.

   - International and traditionally underrepresented submissions are welcome.

   - Private, Public and Startup Companies are welcome to submit.

   - Academic researchers and trainees are welcome to submit.

  NOTE: Case studies are NOT considered whereas, Trials in Progress ARE accepted if they can show a novel trial design or new development.

  POSTER PRESENTATIONS
  If your abstract is selected for a poster, you will need to be available to participate in a poster presentation at the annual meeting. This is scheduled to take place on Thursday, March 13 at 5pm.

  PIPELINE PRESENTATIONS
  Submitted abstracts that most closely conform to the above criteria and the ASENT goals may also be selected for a 10-minute oral presentation (including 2 minute Q&A) at one of our Pipeline Presentation sessions. ASENT encourages abstracts from private, public and startup companies and government or academic labs that contain neurotherapeutic research results.

  The ASENT Annual Meeting attracts leaders in neurotherapeutics from all over the world, in all disease states. Pipeline presentations increase exposure to strategic partners in life sciences who have supported novel approaches through partnerships or strategic investments.  

  Past presenters have reported the following results:

  • increase in stock values in the days following the presentation
  • financially beneficial partnerships as a result of presentation
  • development of new companies as a result of participation in meeting

  For questions regarding abstracts, please email jessica@asent.org.

  Show details
• ASENT 2025 Clinical Trials Course

  • Start
    March 10, 2025
  • End
    March 11, 2025
  • Location
    Hyatt Regency Bethesda, Bethesda MD

  Training in Neurotherapeutic Clinical Trials: Development and Implementation Course

  APPLICATION DEADLINE: OCTOBER 28, 2024

  APPLY TODAY

  DOWNLOAD THE BROCHURE

  About the Course

  • Format: In Person 
  • Application: Free 
  • Tuition: $450 for Accepted Applicants 
  • Requirements: Completed Application 
  • Credentials Provided: Certificate of Completion 
  • Included: Course materials, Discounted Registration for ASENT Annual Meeting, Discounted fee to Submit Abstract to ASENT. 
  • Not Included: Travel and Hotel is not included for all participants

  
  

  ASENT is pleased to offer a 2-day course March 10-11, 2025 at the Hyatt Regency Bethesda, in Bethesda, MD to introduce researchers and clinicians to the principles of neurotherapeutic clinical trial development and implementation. The course will be especially relevant if you are interested in conducting neurotherapeutic clinical trials.

  The course covers the principles of clinical trials from pre-clinical programs to Phase III design and implementation, including necessary regulatory conversations and IND enabling studies, IRB oversight and adverse event tracking and reporting. The course considers clinical trials in the neurotherapeutic space for both drugs and devices. The course will also address the unique challenges inherent in developing treatments for nervous system disorders. 

  The course will feature a mix of:

  • Didactic sessions that go in depth into a wide range of topics

  • Interactive workshops where participants will work in teams on projects such as drafting protocols and addressing adverse events 

  • Panel discussions with lively Q&A 

  • Discounted access to the ASENT Annual Meeting

  APPLY TODAY

  DOWNLOAD THE BROCHURE

  
  

  Participants who attend the course will have ongoing access to senior faculty in attendance in a mentoring capacity. We anticipate that most applicants will have some familiarity with clinical research however, any clinical investigator who would benefit from the course is invited to apply. Those in industry and in private practice are also welcome to apply. The course will be offered annually and participants have discounted access to the ASENT Annual Meeting.

  You will be asked to provide:
  

  • Name
  • Contact Information
  • CV
  • A one page letter of interest

  We are excited to have the opportunity to offer this course, which we believe will help to advance the availability of new drugs for patients with neurological conditions. If your work would benefit from an understanding of neurologic clinical trials you are encouraged to apply.

  APPLY TODAY

  DOWNLOAD THE BROCHURE
  

  
  

  Show details
• ASENT 2025 Annual Meeting

  • Start
    March 12, 2025
  •  
    8:00 AM
  • End
    March 14, 2025
  •  
    1:00 PM
  • Location
    Hyatt Regency Bethesda, Bethesda, MD

  Register

  ABOUT ASENT 2025 Annual Meeting

  The ASENT 2025 Annual Meeting, which will take place March 12 - 14, 2025 at the Hyatt Regency Bethesda in Bethesda, MD, is the premier neuroscience and neurotherapeutics conference where senior leaders from leading payers, providers, employers, investors, fast-growing startups, pharma, policymakers, funders and innovation centers gather with one central focus, improving the process of bringing neurotherapeutics to market.

  The plenary sessions, panel discussions, outstanding pipeline presentations and poster sessions focus on the latest science in neurotherapeutics. The conference content will focus on the latest science in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices. The event features plenary sessions, panel discussions, satellite luncheons, networking meetings, pipeline presentations and poster sessions.

  WHO ATTENDS

  Physician-Scientists | Neurologists | Neuroscientists | Trainees | Drug and Device Companies | CROs | Fellows | Post-docs | Founders | Funders | Industry Leaders | Nonprofit Organizations and Advocacy Groups | Journal Editors | Representatives from NIH, NIA, NIDA, NINDS and FDA

  
  

  Show details